FBT Among Technology ETFs
End-of-day Nov 18, 2026 · 58 Technology ETFs by 1W
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return | 0.0% | −3.0% | −1.8% | −0.5% | +29.2% | +33.3% | +98.9% | +67.3% | +198.9% | +1,024.6% |
| Peer average | +0.3% | −6.2% | −9.7% | −12.1% | +2.0% | +5.0% | +65.2% | +23.5% | +365.5% | — |
| S&P 500 · VOO | −0.3% | −3.9% | −5.0% | −4.0% | +8.0% | +10.9% | +72.4% | +68.9% | +302.1% | — |
$47 of every $1,000 in FBT is Genmab
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | GMABGenmab A/S () | Healthcare | 4.65% | $465.09 | 2.7M | $138.5M |
| 2 | ADMAADMA Biologics | Healthcare | 4.37% | $436.54 | 9.5M | $130.0M |
| 3 | REGNRegeneron Pharmaceuticals | Healthcare | 4.26% | $425.69 | 132K | $126.8M |
| 4 | ONCBeOne Medicines () | Healthcare | 3.87% | $386.84 | 279K | $115.2M |
| 5 | NBIXNeurocrine Biosciences | Healthcare | 3.87% | $386.50 | 694K | $115.1M |
| 6 | ARGXargenx SE () | Healthcare | 3.81% | $381.07 | 120K | $113.5M |
| 7 | EXELExelixis | Healthcare | 3.80% | $379.70 | 1.7M | $113.1M |
| 8 | TGTXTG Therapeutics | Healthcare | 3.76% | $375.80 | 1.8M | $111.9M |
| 9 | GILDGilead Sciences | Healthcare | 3.74% | $373.71 | 654K | $111.3M |
| 10 | ALKSAlkermes | Healthcare | 3.71% | $371.36 | 2.4M | $110.6M |
| 11 | BIIBBiogen | Healthcare | 3.69% | $368.68 | 438K | $109.8M |
| 12 | AMGNAmgen | Healthcare | 3.66% | $366.25 | 238K | $109.1M |
| 13 | TARSTarsus Pharmaceuticals | Healthcare | 3.55% | $354.67 | 1.4M | $105.6M |
| 14 | BMRNBioMarin Pharmaceutical | Healthcare | 3.54% | $354.31 | 1.8M | $105.5M |
| 15 | UTHRUnited Therapeutics | Healthcare | 3.53% | $352.92 | 180K | $105.1M |
of the $347B in 58 Technology ETFs
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | GMAB | Genmab A/S () | 4.65% |
| 2 | ADMA | ADMA Biologics | 4.37% |
| 3 | REGN | Regeneron Pharmaceuticals | 4.26% |
| 4 | ONC | BeOne Medicines () | 3.87% |
| 5 | NBIX | Neurocrine Biosciences | 3.87% |
| 6 | ARGX | argenx SE () | 3.81% |
| 7 | EXEL | Exelixis | 3.80% |
| 8 | TGTX | TG Therapeutics | 3.76% |
| 9 | GILD | Gilead Sciences | 3.74% |
| 10 | ALKS | Alkermes | 3.71% |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 13, 2024 | Dec 31, 2024 | $1.17 |
| Dec 30, 2021 | Jan 10, 2022 | $2.21 |
| Sep 23, 2015 | Sep 30, 2015 | $0.0200 |
| Jun 24, 2015 | Jun 30, 2015 | $0.0650 |
| Mar 25, 2015 | Mar 31, 2015 | $0.0480 |
| Dec 23, 2014 | Dec 31, 2014 | $0.0524 |
| Jun 23, 2008 | Jun 30, 2008 | $0.27 |